Search - tctmd.com

Displaying 41 - 60 of 87

Sort: Relevancy | Date

Presentation THT 2025

Is There a Role for Obesity in the Progression of Heart Failure With a Reduced Ejection Fraction?

Presenter: Javed Butler

February 12, 2025

Presentation THT 2025

Pressure-Volume Loop Derived Left Ventricular Hypercontractility Is Associated With Reduced Long-Term Survival in Heart Failure With Preserved Ejection Fraction

Presenter: Sebastian Roschx

February 12, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

News Conference News THT 2025

Reprieve System Safely Aids Decongestion in Acute HF: FASTR Pilot RCT

Todd Neale

February 11, 2025

Presentation THT 2025

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Presenter: Javed Butler

February 11, 2025

Presentation THT 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Presenter: Arvind Kumar Venkataramana Raju

February 11, 2025

Presentation THT 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

News Conference News THT 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Michael O'Riordan

March 08, 2024

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

Presentation THT 2024

The Role of AF Ablation in HF Across the Spectrum of Ejection Fractions

Presenter: Kevin Makati

March 05, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Presenter: Sanjiv J. Shah

March 05, 2024

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Differences in Medication Changes in in the Sham and Treatment groups of REBALANCE-HF

Presenter: Sheldon E. Litwin

March 04, 2024

Presentation THT 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Stress Blood Volume Analysis

Presenter: Marat Fudim

March 04, 2024

Presentation THT 2024

Association of a Novel, Non-invasive AI Model to Automate Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction (HFpEF) with Invasive Hemodynamics

Presenter: Nadira Hamid

March 04, 2024

News Features THT 2023

The Promise of AI for Improving Health Equity in Heart Failure

Todd Neale

April 04, 2023

Advertisement

Is There a Role for Obesity in the Progression of Heart Failure With a Reduced Ejection Fraction?

Pressure-Volume Loop Derived Left Ventricular Hypercontractility Is Associated With Reduced Long-Term Survival in Heart Failure With Preserved Ejection Fraction

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Reprieve System Safely Aids Decongestion in Acute HF: FASTR Pilot RCT

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

The Role of AF Ablation in HF Across the Spectrum of Ejection Fractions

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Randomized Trial 12-Month Results

Debating the Role of T-TEER in the Sickest Patients

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Differences in Medication Changes in in the Sham and Treatment groups of REBALANCE-HF

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Stress Blood Volume Analysis

Association of a Novel, Non-invasive AI Model to Automate Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction (HFpEF) with Invasive Hemodynamics

The Promise of AI for Improving Health Equity in Heart Failure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content